Journal article
Spending, utilization, and coverage for chronic rhinosinusitis with nasal polyposis therapies among Medicare Advantage beneficiaries
International forum of allergy & rhinology, v 14(10), pp 1643-1646
Oct 2024
PMID: 38923795
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Key points CRSwNP‐specific mean total annual spending ranged from$5,837 (EDS‐FLU) to $ 28,058 (dupilumab). Most CRSwNP patients receiving biologics had comorbid asthma and did not undergo sinus surgery. While biologics were covered by most Medicare Part D plans, only 37% of plans covered EDS‐FLU.
Metrics
1 Record Views
Details
- Title
- Spending, utilization, and coverage for chronic rhinosinusitis with nasal polyposis therapies among Medicare Advantage beneficiaries
- Creators
- Akash M. Bhat - Medical University of South CarolinaZachary M. Soler - Medical University of South CarolinaVinay K. Rathi - Medical University of South CarolinaRodney J. Schlosser - Medical University of South Carolina
- Publication Details
- International forum of allergy & rhinology, v 14(10), pp 1643-1646
- Publisher
- Wiley
- Number of pages
- 4
- Grant note
- Optinose
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001253852300001
- Scopus ID
- 2-s2.0-85196861233
- Other Identifier
- 991022202121704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Otorhinolaryngology